Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities

Inotiv Acquires HistoTox Labs

April 13, 2021

Healthcare Services

Inotiv, Inc. has entered into an agreement to purchase substantially all assets of HistoTox Labs, a histopathology contract research organization, for $22.0 million in cash. The acquisition (subject to financing and customary closing conditions) expands Inotiv's pathology and histology capabilities, adds a Boulder, Colorado facility with digital pathology and immunohistochemistry capabilities, and is expected to retain all HistoTox employees.

Invaio Sciences Acquires Peptyde Bio

December 7, 2023

Biotechnology

Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.

Johnson & Johnson Acquires Proteologix Inc.

May 16, 2024

Biotechnology

Johnson & Johnson has entered into a definitive agreement to acquire privately-held Proteologix, Inc. for $850 million in cash plus potential milestone payments. Proteologix is a San Carlos, California–based biotechnology company developing bispecific antibodies (including PX128 and PX130) for atopic dermatitis and asthma; the deal is expected to close mid-2024 subject to customary conditions.

NanoImaging Services Acquires Proteos

January 5, 2025

Biotechnology

NanoImaging Services (NIS), a cryo-electron microscopy services provider backed by Ampersand Capital Partners, has acquired Proteos, Inc., a Kalamazoo-based CRO specializing in recombinant protein and antibody production. The add-on acquisition integrates Proteos’ protein production capabilities with NIS’s cryo-EM services to create an end-to-end offering for structure-based drug discovery and protein production workflows.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Inotiv Acquires Integrated Laboratory Systems (ILS)

January 10, 2022

Healthcare Services

Inotiv, Inc. (NASDAQ: NOTV) completed the acquisition of Integrated Laboratory Systems, LLC (ILS), a contract research organization based in Morrisville, North Carolina, from Sier Capital. The transaction consideration totaled $56.0 million (approximately $38.0 million cash and 429,118 Inotiv shares valued at $18.0 million); ILS reported roughly $20.0 million of revenue in 2021 and will be integrated to expand Inotiv's genetic toxicology, in vivo/in vitro toxicology, pathology, genomics, and computational toxicology capabilities.